Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.
Company profile
Ticker
TVTX
Exchange
Website
CEO
Eric Dube
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Desert Gateway, Inc., Retrophin, Inc.
SEC CIK
Corporate docs
Subsidiaries
Travere Therapeutics Pharmaceutical, Inc. • Travere Therapeutics Ireland Limited • Travere Therapeutics Switzerland GmbH • Travere Therapeutics US Holdings, LLC • Kyalin Biosciences, Inc. • Manchester Pharmaceuticals LLC ...
IRS number
262383102
TVTX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Travere Therapeutics Announces Proposed Public Offering of Common Stock
1 Mar 23
424B5
Prospectus supplement for primary offering
1 Mar 23
FWP
Free writing prospectus
28 Feb 23
424B5
Prospectus supplement for primary offering
27 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
8-K
Other Events
17 Feb 23
8-K
Travere Therapeutics Provides Corporate Update and 2023 Outlook
9 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 Oct 22
Transcripts
TVTX
Earnings call transcript
2022 Q4
23 Feb 23
TVTX
Earnings call transcript
2022 Q3
28 Oct 22
TVTX
Earnings call transcript
2022 Q2
7 Aug 22
TVTX
Earnings call transcript
2022 Q1
8 May 22
TVTX
Earnings call transcript
2021 Q4
25 Feb 22
TVTX
Earnings call transcript
2021 Q3
29 Oct 21
TVTX
Earnings call transcript
2021 Q2
31 Jul 21
TVTX
Earnings call transcript
2021 Q1
9 May 21
TVTX
Earnings call transcript
2020 Q4
2 Mar 21
TVTX
Earnings call transcript
2020 Q3
8 Nov 20
Latest ownership filings
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
13 Mar 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
MACQUARIE GROUP LTD
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
10 Feb 23
SC 13G/A
JANUS HENDERSON GROUP PLC
10 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G
STATE STREET CORP
6 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 61.69 mm | 61.69 mm | 61.69 mm | 61.69 mm | 61.69 mm | 61.69 mm |
| Cash burn (monthly) | 29.88 mm | 8.67 mm | 22.28 mm | 23.27 mm | 18.21 mm | 15.52 mm |
| Cash used (since last report) | 88.35 mm | 25.64 mm | 65.89 mm | 68.81 mm | 53.85 mm | 45.90 mm |
| Cash remaining | -26.67 mm | 36.05 mm | -4.20 mm | -7.12 mm | 7.84 mm | 15.79 mm |
| Runway (months of cash) | -0.9 | 4.2 | -0.2 | -0.3 | 0.4 | 1.0 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 158 |
| Opened positions | 17 |
| Closed positions | 30 |
| Increased positions | 70 |
| Reduced positions | 53 |
| 13F shares | Current |
|---|---|
| Total value | 1.50 tn |
| Total shares | 75.85 mm |
| Total puts | 53.80 k |
| Total calls | 46.90 k |
| Total put/call ratio | 1.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Armistice Capital | 6.41 mm | $134.84 bn |
| BLK Blackrock | 5.09 mm | $107.13 bn |
| JHG Janus Henderson | 5.09 mm | $107.06 bn |
| Deep Track Capital | 4.58 mm | $96.36 bn |
| STT State Street | 4.22 mm | $88.83 bn |
| Ra Capital Management | 3.98 mm | $83.80 bn |
| MCQEF Macquarie | 3.56 mm | $74.79 bn |
| Vanguard | 3.52 mm | $73.93 bn |
| GS Goldman Sachs | 2.64 mm | $55.52 bn |
| Adage Capital Partners GP, L.L.C. | 2.60 mm | $54.68 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Feb 23 | Sandra Calvin | Common Stock | Sell | Dispose S | No | Yes | 22.42 | 360 | 8.07 k | 42,805 |
| 1 Feb 23 | Sandra Calvin | Common Stock | Sell | Dispose S | No | No | 21.752 | 1,671 | 36.35 k | 43,165 |
| 1 Feb 23 | Eric M Dube | Common Stock | Sell | Dispose S | No | Yes | 22.25 | 8,196 | 182.36 k | 237,150 |
| 1 Feb 23 | Christopher R. Cline | Common Stock | Sell | Dispose S | No | No | 21.752 | 1,588 | 34.54 k | 51,533 |
| 1 Feb 23 | Peter Heerma | Common Stock | Sell | Dispose S | No | No | 21.752 | 1,779 | 38.70 k | 82,069 |
| 31 Jan 23 | Sandra Calvin | Common Stock | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 44,836 |
| 31 Jan 23 | Sandra Calvin | Employee stock option Common Stock | Grant | Acquire A | No | No | 22.4 | 20,000 | 448.00 k | 20,000 |
| 31 Jan 23 | Eric M Dube | Common Stock | Grant | Acquire A | No | No | 0 | 97,500 | 0.00 | 245,346 |
| 31 Jan 23 | Eric M Dube | RSU Common Stock | Grant | Acquire A | No | No | 0 | 32,500 | 0.00 | 32,500 |
| 31 Jan 23 | Eric M Dube | Employee stock option Common Stock | Grant | Acquire A | No | No | 22.4 | 260,000 | 5.82 mm | 260,000 |
News
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
1 Mar 23
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
1 Mar 23
Guggenheim Initiates Coverage On Travere Therapeutics with Buy Rating, Announces Price Target of $37
1 Mar 23
Reported Late Tuesday Feb. 28, Travere Therapeutics Announces Pricing Of $200M Upsized Public Offering Of 8.275M Shares Of Common Stock At A Price Of $21/Share And 1.25M Pre-Funded Warrants
1 Mar 23
Travere Therapeutics's Return On Capital Employed Overview
28 Feb 23
Press releases
Travere Therapeutics to Present at Upcoming Investor Conferences
28 Mar 23
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
23 Mar 23
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Mar 23
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
14 Mar 23
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters' Option to Purchase Additional Shares
3 Mar 23